TY - JOUR
T1 - Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients
AU - Ohta, Yasuyuki
AU - Yamashita, Toru
AU - Nomura, Emi
AU - Hishikawa, Nozomi
AU - Ikegami, Ken
AU - Osakada, Yosuke
AU - Matsumoto, Namiko
AU - Kawahara, Yuko
AU - Yunoki, Taijun
AU - Takahashi, Yoshiaki
AU - Takamiya, Motonori
AU - Tadokoro, Koh
AU - Sasaki, Ryo
AU - Nakano, Yumiko
AU - Tsunoda, Keiichiro
AU - Sato, Kota
AU - Omote, Yosio
AU - Takemoto, Mami
AU - Abe, Koji
N1 - Funding Information:
We thank all the patients for their participation and Dr. Takayuki Maruyama for technical assistance in our study. This work was partly supported by a Grant-in-Aid for Scientific Research (B) 17H0419611 , (C) 15K0931607 , 17H0975609 , and 17K1082709 , and by Grants-in-Aid from the Research Committees (Kaji R, Toba K, and Tsuji S) from the Japan Agency for Medical Research and Development 7211700121 , 7211800049 and 7211800130 .
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Background: The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS). Our objective was to evaluate the therapeutic effects of edaravone for oxidative stress and anti-oxidative activity in ALS patients. Methods: Twenty-two ALS patients with a disease duration of 2 years, treated by edaravone, and 25 control participants were evaluated according to their clinical scores, including ALS functional rating scale-revised (ALSFRS-R), and serum and cerebrospinal fluid (CSF) markers of oxidative stress dROM and anti-oxidative activity OXY. Results: Serum and CSF markers of anti-oxidative activity OXY were significantly decreased in ALS patients at pre-treatment compared with controls (##p < .01), which was improved in the course of edaravone treatment. Both serum and CSF OXY were significantly correlated with ALS clinical scores including ALSFRS-R (*p < .05, **p < .01, ***p < .001). Furthermore, serum OXY at pre-treatment was significantly correlated with a change in the ALSFRS-R score in the sixth cycle of edaravone treatment (*p < .05). Conclusions: The present study suggests significant correlations between anti-oxidative activity and ALS clinical severity, and the therapeutic efficacy of edaravone for decreased anti-oxidative activity in ALS.
AB - Background: The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS). Our objective was to evaluate the therapeutic effects of edaravone for oxidative stress and anti-oxidative activity in ALS patients. Methods: Twenty-two ALS patients with a disease duration of 2 years, treated by edaravone, and 25 control participants were evaluated according to their clinical scores, including ALS functional rating scale-revised (ALSFRS-R), and serum and cerebrospinal fluid (CSF) markers of oxidative stress dROM and anti-oxidative activity OXY. Results: Serum and CSF markers of anti-oxidative activity OXY were significantly decreased in ALS patients at pre-treatment compared with controls (##p < .01), which was improved in the course of edaravone treatment. Both serum and CSF OXY were significantly correlated with ALS clinical scores including ALSFRS-R (*p < .05, **p < .01, ***p < .001). Furthermore, serum OXY at pre-treatment was significantly correlated with a change in the ALSFRS-R score in the sixth cycle of edaravone treatment (*p < .05). Conclusions: The present study suggests significant correlations between anti-oxidative activity and ALS clinical severity, and the therapeutic efficacy of edaravone for decreased anti-oxidative activity in ALS.
KW - ALS
KW - Anti-oxidative activity
KW - Edaravone
KW - OXY
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85084830988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084830988&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2020.116906
DO - 10.1016/j.jns.2020.116906
M3 - Article
C2 - 32446009
AN - SCOPUS:85084830988
SN - 0022-510X
VL - 415
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 116906
ER -